Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28795540 | 0.93 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| Succinimide SCHEMBL25387343 | 0.89 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL16132816 | 0.85 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL1395632 | 0.85 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL7421417 | 0.84 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL28118108 | 0.83 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL23235923 | 0.82 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL29139348 | 0.81 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL23235912 | 0.80 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL30733309 | 0.80 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1583 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3878861-B1 | CL AND/OR CH1 MUTATED ANTIBODIES FOR DRUG CONJUGATION | LONZA AG (CH) | 2025-05-07 | — | — | EP | claimed |
| US-20240239885-A1 | ANTIBODY CONJUGATE COMPRISING ANTI-P-CADHERIN ANTIBODY AND USES THEREOF | WuXi Biologics Ireland Limited (IE) | 2024-07-18 | — | — | US | claimed |
| US-20240156978-A1 | MAYTANSINE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2024-05-16 | — | — | US | claimed |
| WO-2024044550-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| US-20240043512-A1 | EPITOPES OF ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES | IMCARE BIOTECH LLC | 2024-02-08 | — | — | US | claimed |
| EP-4313009-A1 | MAYTANSINE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| US-11866496-B2 | Humanized anti-CD79B antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2024-01-09 | — | — | US | claimed |
| EP-4294845-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-11833222-B2 | CL and/or CH1 mutated antibodies for drug conjugation | LONZA LTD (CH) | 2023-12-05 | — | — | US | claimed |
| US-20230372518-A1 | ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-11-23 | — | — | US | claimed |
| WO-2008052187-A2 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH. INC. (US) | 2008-05-02 | — | — | WO | claimed |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-02-28 | — | — | US | claimed |
| WO-2007140371-A2 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2007-12-06 | — | — | WO | claimed |
| EP-1812465-A1 | NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | Genentech, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1786838-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006054961-A2 | NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | GENENTECH, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| WO-2006029183-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20050272118-A1 | Novel composition and methods for the treatment of immune related diseases | GENENTECH, INC. | 2005-12-08 | — | — | US | claimed |
| US-20050106644-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107595-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. | 2005-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239885-A1 | ANTIBODY CONJUGATE COMPRISING ANTI-P-CADHERIN ANTIBODY AND USES THEREOF | CDH1, EPCAM, VIM | ALDH1A1 964/4885SMN1; SMN2 4095/4885HPGD 2865/4885 |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | CD22, CD2BP2, CD2 | ALDH1A1 404/4885SMN1; SMN2 3912/4885HPGD 3038/4885 |
| US-11866496-B2 | Humanized anti-CD79B antibodies and immunoconjugates and methods of use | CD99, CD79B, CD47 | ALDH1A1 2739/4885SMN1; SMN2 2389/4885HPGD 4019/4885 |
| US-20230372518-A1 | ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | TAP1, HM13, TMSB4X | ALDH1A1 3942/4885SMN1; SMN2 1303/4885HPGD 4446/4885 |
| US-20240156978-A1 | MAYTANSINE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | TM9SF4, TMSB4X, TM9SF2 | ALDH1A1 2070/4885SMN1; SMN2 1107/4885HPGD 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.